Regeneron, Sensei in clinical supply agreement for tumor studies

Jan. 05, 2023 9:19 AM ETRegeneron Pharmaceuticals, Inc. (REGN), SNSEBy: Dulan Lokuwithana, SA News Editor

Solution Concept with Handshake on Chalkboard Background


  • Cancer-focused biotech Sensei Biotherapeutics (NASDAQ:SNSE) announced a clinical supply agreement with Regeneron (NASDAQ:REGN) on Thursday to source the latter’s anti-PD1 therapy Libtayo (cemiplimab) for studies targeted at solid tumors.
  • Per the terms, Regeneron (REGN) will provide Libtayo

This was corrected on 01/05/2023 at 9:29 AM. A previous version of this article included an incorrect ticker symbol for Sensei Biotherapeutics. The amended version reflects the correct ticker for the company.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.